RNA therapeutics is arguably at the forefront of the treatment for a number of complex medical disorders. From Oncological implications to cardiovascular disease, the investigation into the mechanisms which inhibit specific gene transcription could provide the key to the eradication of a number of diseases. SMi’s 2013 RNA Therapeutics conference will look to discuss and share some of the latest findings and research in the field of RNAi technologies and the delivery mechanisms by which these therapies are administered to their target tissues.
A selection of distinguished speakers will look to provide the latest insights into some of the most promising technologies in RNAi development and delivery as well as addressing some of the current IP and regulatory challenges faced in the development and protection of these technologies.
Developing an understanding in how Epigenetic mechanisms can be used to alter gene expression is undoubtedly a prime target for the development of compounds which offer the ability to alter the processes of translation of a peptide. SMi’s 2013 RNA Therapeutics conference offers the chance to meet the industry leaders in this field and provides the perfect opportunity to network and identify new strategies for RNAi development and application.
The field of genetic medicine and the process of manipulating gene expression is still relatively new and as such evolves continuously at an almost alarming rate. SMi’s 2013 event will look to address the timeliest, ground breaking research that has been carried out throughout 2012 and into 2013 and address the future implications of these findings. Testimonials from our highly successful event in 2012 include:
“Enjoyable conference” – Thermo Fisher Scientific
“Great Overview of Novel Approaches” – GlaxoSmithKline
“Very exciting Data” – Novartis Pharma
- Identify new delivery technologies which enhance the efficacy and bioavailability of your compounds for the appropriate tissue
- Discover new approaches in the field of RNAi technologies
- Evaluate the current landscape with respect to the current technologies and how these are being applied
- Network with some of the industry leaders within the field of RNA therapeutics
- Overcome the challenges of developing RNAi technologies and the mechanisms by which they alter gene expression
SMi's RNA Therapeutics event is a must attend for the following:
Formulation Scientist
Research assistants
Research Scientists
Clincal scientist
Biomedical scientists
Academics
Biotechnology
Post Doctoral Fellows
Clinical Investigator
Pharmacologists
Medicinal Chemists
AstraZeneca; AuraSense Therapeutics LLC; Avidity IP; Centro Hospitalar de Tras-os-Montes e Alto Douro; Chemconsilium; Cliniques Universitaires UCL de Mont-Godinne; Covington & Burling Llp; Faculty Of Pharmacy University Lisbon; GlaxoSmithKline; GSK; Imperial College London; Institute of Cancer Research; InteRNA Technologies; Kilburn & Strode; King Saud University; Kings College London; Kings College University; Merck & Co Inc; Octo Plus; Pierre Fabre Medicaments; Queen Mary And Westfield College; Sanofi-Aventis Deutschland GmbH; Silence Therapeutics AG; Sylentis; UCL Institute of Child Health; UMC Utrecht; Universite Paris Sud; University College London; University Of Southampton; University Paris Sud; Weill Cornell Medical College in Qatar; Yale University;